The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The Respiratory Biologics Market By The End Of 2030?
The respiratory biologics market has seen swift expansion in recent years. Its value is expected to increase from $7.41 billion in 2025 to $8.61 billion in 2026, with a compound annual growth rate (CAGR) of 16.3%. The drivers behind its historical growth include the shortcomings of traditional inhalers, a rise in severe asthma occurrences, the authorization of biologic therapies, advances in immunology research, and the proliferation of specialty clinics.
The respiratory biologics market size is projected to experience substantial growth over the coming years. This market is anticipated to reach $15.66 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.1%. Several factors will fuel this expansion during the forecast period, including the advancement of precision respiratory medicine, the broadening of biologics pipelines, increasing healthcare expenditures, enhanced reimbursement strategies, and the persistent unmet needs in severe respiratory diseases. Key trends foreseen within this period encompass a growing uptake of targeted biologic therapies, an increase in severe asthma treatment options, the development of biomarker-driven patient selection, the rising application of injectable respiratory medications, and a movement towards long-acting biologic agents.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp
What Primary Drivers Are Shaping The Development Of The Respiratory Biologics Market?
The expansion of the respiratory biologics market is projected to be fueled by the escalating levels of air pollution in the coming years. Air pollution is defined by the presence of noxious substances, including gases, particulate matter, and biological molecules, within the Earth’s atmosphere, which are detrimental to both human health and the environment. This increase in air pollution is a consequence of intensifying industrialization and urbanization, leading to greater emissions of harmful agents from factories, vehicles, and construction sites. Respiratory biologics play a crucial role in mitigating the health impacts caused by air pollution through targeted therapeutic interventions that reduce inflammation and enhance lung function in individuals exposed to atmospheric pollutants. For example, in January 2025, the Environmental Protection Agency, a US-based government agency, indicated that the United States discharged over 66 million tons of pollutants into the atmosphere in 2023. Thus, the surge in air pollution is a key factor propelling the development of the respiratory biologics market.
Which Segment Classifications Shape The Respiratory Biologics Market?
The respiratory biologics market covered in this report is segmented –
1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies
Subsegments:
1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma
2) By Chronic Rhinosinasitis: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps
3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES
How Are Trends Impacting The Respiratory Biologics Market?
Leading companies in the respiratory biologics market are concentrating on developing advanced biologic therapies, such as specialized immune therapies for chronic respiratory diseases. Their goal is to offer precise treatments that can reduce inflammation and improve lung function. These targeted immune therapies for chronic respiratory diseases work by helping to control the body’s defense system, thereby lessening swelling and breathing issues in long-term lung conditions. For instance, in September 2024, Sanofi S.A., a pharmaceutical company from France, announced that the US Food and Drug Administration (FDA) had approved Dupixent (dupilumab) for use as an add-on maintenance therapy for adults with chronic obstructive pulmonary disease (COPD) that was inadequately controlled and presented an eosinophilic phenotype. This approval represented a significant accomplishment, as Dupixent became the first biologic medicine to be authorized in the US for treating this particular patient group with COPD.
Which Companies Are Expanding Their Footprint In The Respiratory Biologics Market?
Major companies operating in the respiratory biologics market are Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Amgen Inc., Swedish Orphan Biovitrum AB, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Glenmark Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.
Read the full respiratory biologics market report here:
https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report
How Does The Respiratory Biologics Market Perform Across Major Global Regions?
North America was the largest region in the respiratory biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Respiratory Biologics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp
Browse Through More Reports Similar to the Global Respiratory Biologics Market 2026, By The Business Research Company
Respiratory Devices And Equipment Therapeutic And Diagnostic Market Report 2026
Respiratory Devices And Equipment Therapeutic Market Report 2026
Respiratory Disease Testing Market Report 2026
https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model